Standardisation of costs: the Dutch Manual for Costing in economic evaluations.

Abstract:

:The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements for studies to be considered when deciding on the reimbursement of new medical therapies. Recently, the Dutch Manual for Costing: Methods and Standard Costs for Economic Evaluations in Health Care (further referred to as "the manual") has been published, in addition to the Dutch guidelines for pharmacoeconomic research. The objectives of this article are to describe the main content of the manual and to discuss some key issues of the manual in relation to the standardisation of costs. The manual introduces a six-step procedure for costing. These steps concern: the scope of the study;the choice of cost categories;the identification of units;the measurement of resource use;the monetary valuation of units; andthe calculation of unit costs. Each step consists of a number of choices and these together define the approach taken. In addition to a description of the costing process, five key issues regarding the standardisation of costs are distinguished. These are the use of basic principles, methods for measurement and valuation, standard costs (average prices of healthcare services), standard values (values that can be used within unit cost calculations), and the reporting of outcomes. The use of the basic principles, standard values and minimal requirements for reporting outcomes, as defined in the manual, are obligatory in studies that support submissions to acquire reimbursement for new pharmaceuticals. Whether to use standard costs, and the choice of a particular method to measure or value costs, is left mainly to the investigator, depending on the specific study setting. In conclusion, several instruments are available to increase standardisation in costing methodology among studies. These instruments have to be used in such a way that a balance is found between standardisation and the specific setting in which a study is performed. The way in which the Dutch manual tries to reach this balance can serve as an illustration for other countries.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Oostenbrink JB,Koopmanschap MA,Rutten FF

doi

10.2165/00019053-200220070-00002

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

443-54

issue

7

eissn

1170-7690

issn

1179-2027

pii

200702

journal_volume

20

pub_type

杂志文章
  • Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety.

    abstract:BACKGROUND:The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications. O...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0587-0

    authors: Najafzadeh M,Garces JA,Maciel A

    更新日期:2017-12-01 00:00:00

  • Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.

    abstract::Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321020-00001

    authors: Cohen BJ

    更新日期:2003-01-01 00:00:00

  • Economic aspects of general anaesthesia.

    abstract::Proper economic evaluation involves comparative analysis of alternative courses of action in terms of both costs and outcome. This is difficult for general anaesthesia as there are few alternatives and measurement of outcome is difficult to define. All that is generally available is a cost description of different a...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199303020-00005

    authors: Rhodes SP,Ridley S

    更新日期:1993-02-01 00:00:00

  • Anaemia of prematurity. Epidemiology, management and costs.

    abstract::Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199712040-00002

    authors: Meyer MP

    更新日期:1997-10-01 00:00:00

  • A methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection.

    abstract::The aim of this article was to perform a detailed methodological review of models used to estimate the cost effectiveness of drug treatment regimens for HIV infection in Europe and North America and assess the relationship between the different modeling approaches or key structural assumptions and the results. Electro...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-013-0098-6

    authors: Mauskopf J

    更新日期:2013-11-01 00:00:00

  • Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.

    abstract:OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11310110-000000000-00000

    authors: Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

    更新日期:2009-01-01 00:00:00

  • Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

    abstract:BACKGROUND:In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that have therapeutic added value in com...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11539850-000000000-00000

    authors: Hoomans T,Severens JL,van der Roer N,Delwel GO

    更新日期:2012-03-01 00:00:00

  • Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.

    abstract::Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st century. Whilst Japan has s...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11538360-000000000-00000

    authors: Kamae I

    更新日期:2010-01-01 00:00:00

  • Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

    abstract::The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11595920-000000000-00000

    authors: Yang H,Craig D,Epstein D,Bojke L,Light K,Bruce IN,Sculpher M,Woolacott N

    更新日期:2012-04-01 00:00:00

  • Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.

    abstract:BACKGROUND AND OBJECTIVE:Accurate prediction of relevant outcomes is important for targeting therapies and to support health economic evaluations of healthcare interventions in patients with diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) risk equations are some of the most frequently used risk equation...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00822-4

    authors: Laxy M,Schöning VM,Kurz C,Holle R,Peters A,Meisinger C,Rathmann W,Mühlenbruch K,Kähm K

    更新日期:2019-12-01 00:00:00

  • What's good and bad about contraceptive products?: a best-worst attribute experiment comparing the values of women consumers and GPs.

    abstract:BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11598040-000000000-00000

    authors: Knox SA,Viney RC,Street DJ,Haas MR,Fiebig DG,Weisberg E,Bateson D

    更新日期:2012-12-01 00:00:00

  • A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

    abstract::A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11539450-000000000-00000

    authors: Oremus M,Aguilar SC

    更新日期:2011-02-01 00:00:00

  • Costs of irritable bowel syndrome in the UK and US.

    abstract::Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated prevalence rate in the general population of 10-15% in industrialised countries. Although IBS is not a life-threatening disease, it contributes significantly to a large segment of healthcare resource consu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200624010-00002

    authors: Maxion-Bergemann S,Thielecke F,Abel F,Bergemann R

    更新日期:2006-01-01 00:00:00

  • Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patients.

    abstract::This study evaluated the cost of sequential treatment with once-daily ofloxacin or twice-daily ciprofloxacin in 474 hospitalised patients in different countries. The patients were treated intravenously for at least 3 days, then orally for 7 to 10 days or for 3 days beyond the disappearance of infection-related symptom...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199711040-00007

    authors: Salewski E,Bassaris HP,Calangu S,Kitzes R,Kosmidis J,Raz R,Kompan L

    更新日期:1997-04-01 00:00:00

  • Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.

    abstract:OBJECTIVE:To evaluate the cost effectiveness of dabrafenib versus dacarbazine and vemurafenib as first-line treatments in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Canadian healthcare system perspective. METHODS:A partitioned-survival analysis model with three mutually exclus...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-014-0241-z

    authors: Delea TE,Amdahl J,Wang A,Amonkar MM,Thabane M

    更新日期:2015-04-01 00:00:00

  • Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.

    abstract:OBJECTIVE:The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS:A sys...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-018-0668-8

    authors: Rodriguez-Martinez CE,Sossa-Briceño MP,Castro-Rodriguez JA

    更新日期:2018-10-01 00:00:00

  • Introduction to the pharmacoeconomics of herbal medicines.

    abstract::This article explores the need to perform pharmacoeconomic evaluations of herbal medicines and assesses the extent to which this approach has been applied so far to these products. There seems to be no compelling need for pharmacoeconomic analyses of herbal over-the-counter medicines, but such analyses are certainly w...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200018010-00001

    authors: De Smet PA,Bonsel G,Van der Kuy A,Hekster YA,Pronk MH,Brorens MJ,Lockefeer JH,Nuijten MJ

    更新日期:2000-07-01 00:00:00

  • 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

    abstract::To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11312720-000000000-00000

    authors: Neumann PJ,Fang CH,Cohen JT

    更新日期:2009-01-01 00:00:00

  • Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    abstract::As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-016-0472-2

    authors: Carroll C,Tappenden P,Rafia R,Hamilton J,Chambers D,Clowes M,Durrington P,Qureshi N,Wierzbicki AS

    更新日期:2016-11-16 00:00:00

  • Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.

    abstract:UNLABELLED:Cyclosporin microemulsion (Neoral) is a self-emulsifying preconcentrate of cyclosporin which is more rapidly and consistently absorbed than the original oil-based formulation of cyclosporin (standard formulation; Sandimmun, Sandimmune). This superior pharmacokinetic profile suggests that cyclosporin microemu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199814060-00009

    authors: Coukell AJ,Plosker GL

    更新日期:1998-12-01 00:00:00

  • Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

    abstract:OBJECTIVE:To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321070-00005

    authors: Maetzel A,Ruof J,Covington M,Wolf A

    更新日期:2003-01-01 00:00:00

  • Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK.

    abstract:BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523080-00004

    authors: Matza LS,Secnik K,Mannix S,Sallee FR

    更新日期:2005-01-01 00:00:00

  • Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.

    abstract:BACKGROUND:Economic models are considered to be important, as they help evaluate the long-term impact of diabetes treatment. To date, it appears that no article has reviewed and critically appraised the cost-effectiveness models developed to evaluate new oral treatments [glucagon-like peptide-1 (GLP-1) receptor agonist...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-013-0117-7

    authors: Asche CV,Hippler SE,Eurich DT

    更新日期:2014-01-01 00:00:00

  • Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

    abstract::Diseases of the prostate currently represent a major health problem worldwide. As the age of the male population increases in the future, so will the number of patients suffering from these disorders and the cost for treatment increase. Currently, benign prostatic hyperplasia (BPH) and prostate cancer are common in ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199201050-00007

    authors: Amin EA,Amin M

    更新日期:1992-05-01 00:00:00

  • Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

    abstract:BACKGROUND:There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases. OBJECTIVE:This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a so...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200927060-00003

    authors: Rutten-van Mölken MP,Hoogendoorn M,Lamers LM

    更新日期:2009-01-01 00:00:00

  • Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.

    abstract:OBJECTIVE:To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective was to estimate the relationship between disease progression and institutionalisation. DESIGN AND SETTING:We assessed the relation...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200017040-00005

    authors: Hauber AB,Gnanasakthy A,Snyder EH,Bala MV,Richter A,Mauskopf JA

    更新日期:2000-04-01 00:00:00

  • Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.

    abstract:BACKGROUND:Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40273-013-0054-5

    authors: Parthan A,Leahy KJ,O'Sullivan AK,Iakoubova OA,Bare LA,Devlin JJ,Weinstein MC

    更新日期:2013-06-01 00:00:00

  • A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma.

    abstract:BACKGROUND:Assessment of health state and health-related quality of life (HR-QOL) are limited by a child's age and cognitive ability. Parent-proxy reports are known to differ from children's reports. Simultaneous assessment using a parent-child dyad is an alternative approach. OBJECTIVE:Our objective was to assess the...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11597890-000000000-00000

    authors: Ungar WJ,Boydell K,Dell S,Feldman BM,Marshall D,Willan A,Wright JG

    更新日期:2012-08-01 00:00:00

  • An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.

    abstract::Since the inception of the National Health Service in 1948, successive British governments have taken various measures to restrain the growth of the medicines bill. A total of 10 different measures have been introduced with very limited success. The most effective measures have been those directed at increasing the le...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199610030-00003

    authors: Griffin JP

    更新日期:1996-09-01 00:00:00

  • A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

    abstract:OBJECTIVE:The study aimed to conduct a systematic literature search to identify health state utilities for weight change in type 2 diabetes mellitus (T2DM) and to review those values for appropriateness for inclusion in a submission to the National Institute for Health and Clinical Excellence (NICE). METHODS:The searc...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11599420-000000000-00000

    authors: Doyle S,Lloyd A,Moore L,Ray J,Gray A

    更新日期:2012-12-01 00:00:00